Theofibrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526446

CAS#: 54504-70-0

Description: Theofibrate, also known as Etofylline clofibrate, is an agent shown to lower blood lipid levels. Etofylline clofibrate is suitable for the treatment of hyperlipoproteinaemia with elevated triglycerides and cholesterol.


Chemical Structure

img
Theofibrate
CAS# 54504-70-0

Theoretical Analysis

MedKoo Cat#: 526446
Name: Theofibrate
CAS#: 54504-70-0
Chemical Formula: C19H21ClN4O5
Exact Mass: 420.12
Molecular Weight: 420.850
Elemental Analysis: C, 54.23; H, 5.03; Cl, 8.42; N, 13.31; O, 19.01

Price and Availability

Size Price Availability Quantity
25mg USD 190
50mg USD 350
100mg USD 550
200mg USD 850
500mg USD 1250
1g USD 1850
Bulk inquiry

Synonym: Theofibrate; Etofylline clofibrate; Etofyllineclofibrate; Duolip.

IUPAC/Chemical Name: Propionic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl) ethyl ester

InChi Key: KYAKGJDISSNVPZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3

SMILES Code: CC(C)(OC1=CC=C(Cl)C=C1)C(OCCN2C=NC(N(C)C(N3C)=O)=C2C3=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 420.850000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ditschuneit HH, Hutt V, Klör HU, Ditschuneit H. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)]. Arzneimittelforschung. 1980;30(11b):2063-7. German. PubMed PMID: 7194061. 2: Ujházy E, Onderová E, Horáková M, Bencová E, Durisová M, Nosál R, Balonová T, Zeljenková D. Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice. Pharmacol Toxicol. 1989 Mar;64(3):286-90. PubMed PMID: 2726692. 3: Rajecová E, Klimes I, Seböková E, Rychnavská E, Pleváková L, Linke-Cvrkalová A, Langrová H. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy]. Vnitr Lek. 1995 Oct;41(10):677-81. Slovak. PubMed PMID: 8578698. 4: Sim AK, Davies ME, McCraw AP, Metz G. Effect of etofylline clofibrate on experimental thrombosis and platelet function. Arzneimittelforschung. 1980;30(11b):2042-5. PubMed PMID: 7194057. 5: Schneider J, Mühlfellner G, Mühlfellner O, Hausmann L, Schubotz R. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. Arzneimittelforschung. 1980;30(11b):2059-62. German. PubMed PMID: 7194060. 6: Metz G, Sim AK, McCraw AP, Cleland ME. Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation. Arzneimittelforschung. 1986 Sep;36(9):1363-5. PubMed PMID: 3539125. 7: Ziegler WJ, Metz G, Specker M. [Clinical effects and tolerance of etofylline clofibrate]. Arzneimittelforschung. 1980;30(11b):2053-8. German. PubMed PMID: 7194059. 8: Vorberg G, Ziegler WJ. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)]. Arzneimittelforschung. 1980;30(11b):2068-72. German. PubMed PMID: 7194062. 9: Sterner W, Chibanguza G, Metz G. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)]. Arzneimittelforschung. 1980;30(11b):2038-41. German. PubMed PMID: 7194056. 10: Lücker PW, Wetzelsberger K, Erking W, Donike M. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. Arzneimittelforschung. 1980;30(11b):2045-53. German. PubMed PMID: 7194058. 11: Ziegler WJ. [On the uricosuric activity of etofylline clofibrate (author's transl)]. Arzneimittelforschung. 1980;30(11b):2073-4. German. PubMed PMID: 7194063. 12: Davies JE, Kellett DN. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents. Arzneimittelforschung. 1980;30(11b):2035-7. PubMed PMID: 7194055. 13: Sterner W, Korn WD. [Pharmacology and toxicology of etofylline clofibrate]. Arzneimittelforschung. 1980;30(11b):2023-31. German. PubMed PMID: 7194053. 14: Metz G, Specker M. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)]. Arzneimittelforschung. 1980;30(11b):2014-9. German. PubMed PMID: 7194051. 15: Ginocchio AV, Metz G. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats. Arzneimittelforschung. 1980;30(11b):2032-4. PubMed PMID: 7194054. 16: Ritschel WA, Thompson GA, Lücker PW, Wetzelsberger K. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation. Arzneimittelforschung. 1980;30(11b):2020-3. PubMed PMID: 7194052. 17: Kłosiewicz-Latoszek L, Szostak WB. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur J Clin Pharmacol. 1991;40(1):33-41. PubMed PMID: 2060543. 18: Sim AK, Spencer A, Metz G, Rushton B. Effect of hypolipidaemic drugs on hepatomegaly and micro-bodies in the rat. A new approach to the nature of hepatic peroxisomal proliferation. Arzneimittelforschung. 1981;31(7):1119-26. PubMed PMID: 7196761. 19: Föger B, Tröbinger G, Ritsch A, Lechleitner M, Hopferwieser T, Menzel HJ, Utermann G, Pfeiffer KP, Patsch JR. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Atherosclerosis. 1995 Oct;117(2):253-61. PubMed PMID: 8801871. 20: Raslová K, Hucková M. [Etophylline clofibrate in the treatment of familial combined hyperlipoproteinemia]. Vnitr Lek. 1995 Apr;41(4):240-2. Slovak. PubMed PMID: 7762188.